Navigation Links
Amarillo Biosciences Appoints Dr. Stephen Chen as Chairman and CEO
Date:2/22/2012

AMARILLO, Texas, Feb. 22, 2012 /PRNewswire/ -- Amarillo Biosciences, Inc. (OTCBB: AMAR) today announced that Dr. Stephen T. Chen has been appointed as Chairman of the Board and Chief Executive Officer.  Dr. Joseph Cummins will remain as President and become Chief Operating Officer. Dr. Chen has been a director of the company since February 1996. He received a PhD degree in Industrial and Physical Pharmacy from Purdue University in 1977 with an emphasis on drug delivery systems.

Dr. Chen has over thirty years of international business experience, including an extensive background in pharmaceutical product acquisition and licensing, development of joint venture agreements, execution of business strategy, and leadership of start-up companies in the pharmaceutical, biotechnology and nutraceutical industries. Dr. Chen has held executive positions in R&D and business development at several major pharmaceutical companies, including Burroughs Wellcome (presently GlaxoSmithKline), Miles Pharmaceuticals (presently Bayer), ICI America (presently AstraZeneca), and Ciba-Geigy (presently Novartis).

About Amarillo Biosciences

Amarillo Biosciences, Inc. is a U.S. biotechnology firm operating in global partnership with the Hayashibara Group, which also holds 4% of Amarillo Biosciences shares and has provided over $18 million in loans, grants and equity investments. The Company's primary focus is extensive and ongoing R&D into the use of low-dose, orally administered interferon as a treatment for a variety of conditions, including influenza, hepatitis C, chronic cough, and opportunistic infections in patients who are HIV positive. The Company has invested nearly $40 million to establish oral interferon as a therapeutic agent. The majority of those funds were invested in clinical trials in an effort to achieve FDA approval for interferon. Additional information is available on the web at http://www.amar
'/>"/>

SOURCE Amarillo Biosciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. Amarillo Biosciences Issues Corporate Update
2. Amarillo Biosciences Teams with Animal Shelters to Improve Health and Enhance Immunity of Cats and Dogs
3. Neurocrine Biosciences to Present at the Citi 2012 Global Health Care Conference
4. GeneLink Biosciences Completes Sale of GeneWize Life Sciences
5. Ambit Biosciences to Present at Two Upcoming Investor Conferences
6. Neurocrine Biosciences to Present at the 14th Annual BIO CEO & Investor Conference
7. Sangamo BioSciences Announces Fourth Quarter and Full Year 2011 Conference Call and Webcast
8. Sofie Biosciences Is Awarded a US Patent on a Family of Novel PET Probes for Use in Oncology and Immunology
9. Sangamo BioSciences Announces Presentation at J.P. Morgan Healthcare Conference
10. Sangamo BioSciences Announces Presentation of New Data from ZFP Therapeutic® Program in Hemophilia B at American Society for Hematology Meeting
11. Coronado Biosciences Announces Phase 1 Results of CNDO-109 in AML to be Presented at the American Society of Hematology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/19/2013)... June 19, 2013 ... presents Innovative Drug Delivery Systems: ... Licensing Opportunities for Generic Pharmaceutical ... There are more than ... drugs approved all over the ...
(Date:6/19/2013)... Applied Rigaku Technologies, Inc. is pleased to ... of sulfur in ultra-low sulfur diesel (ULSD) using the ... analyzer . The analysis detailed in Rigaku Application Note ... This International Standard specifies an energy dispersive X-ray fluorescence ... in automotive gasoline. , Regulations around the world have ...
(Date:6/19/2013)... Adding to their already extensive supply of ... Dropette® and Heathrow Scientific disposable plastic transfer ... biology, chemistry and any type of liquid handling analysis ... years, Simport has been supplying the science community with ... Simport Dropette®. Simport’s Dropette® is a one-piece plastic ...
(Date:6/18/2013)... KONG, June 18, 2013 China Cord Blood ... "Company"), China,s leading provider of cord blood collection, laboratory ... services, today announced its preliminary unaudited financial results for ... 2013 ended March 31, 2013. Fourth ... the fourth quarter of fiscal 2013 increased by 33.3% ...
Breaking Biology Technology:Innovative Drug Delivery Systems: Novel Product and Formulation Technology Licensing Opportunities for Generic Pharmaceutical Companies 2Innovative Drug Delivery Systems: Novel Product and Formulation Technology Licensing Opportunities for Generic Pharmaceutical Companies 3Rigaku Publishes New Application Note for Analysis of ULSD Per ISO 13032 2Leading Pipette Distributor Pipette.com Now Stocks Transfer Pipettes: Simport’s Dropette and Heathrow Scientific Disposable Plastic Transfer Pipettes 2China Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2013 2China Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2013 3China Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2013 4China Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2013 5China Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2013 6China Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2013 7China Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2013 8China Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2013 9China Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2013 10China Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2013 11China Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2013 12China Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2013 13
... 3 Advanced Life Sciences Holdings,Inc. (Nasdaq: ... and commercialization of novel drugs in the therapeutic areas ... Company,will make a corporate presentation to investors on Tuesday, ... will be delivered in the Windsor Suite,at The Waldorf ...
... (Nasdaq: ONTY ) (TSX:ONY), a biotechnology company ... the treatment of cancer, today announced that Robert Kirkman, ... the 11th Annual BIO CEO & Investor Conference in ... Monday, February 9, 2009. , A live and archived ...
... EMERYVILLE, Calif., Feb. 3 Neurobiological,Technologies, Inc. (NTI(R)) (Nasdaq: ... a,quarterly royalty payment of approximately $1.5 million from Merz,Pharmaceuticals ... of,Alzheimer,s disease. Under an exclusive marketing agreement, NTI ... by Merz and,its marketing partners. , ...
Cached Biology Technology:Advanced Life Sciences to Present at the 11th Annual BIO CEO & Investor Conference 2Advanced Life Sciences to Present at the 11th Annual BIO CEO & Investor Conference 3
(Date:6/19/2013)... (EMA) approved the modified adeno-associated virus AAV-LPL S447X ... use in the Western world. uniQure, a Dutch ... treatment of a rare inherited metabolic disease called ... or two out of one million people. The ... Afflicted individuals carry a defect in the gene ...
(Date:6/18/2013)... Department,s National Renewable Energy Laboratory (NREL), and the ... describing a novel cellulose-degrading enzyme from a marine ... as the gribble. , Gribbles are biologically ... to produce their own enzymes instead of using ... eat. New biomass-degrading enzymes from novel sources such ...
(Date:6/18/2013)... Medical Research Council, Laboratory of Molecular Biology, has ... ICAAC Young Investigator Award. Torrent is being recognized ... first algorithm to predict antimicrobial regions in proteins. ... are now applying this algorithm to interrogate full ... leads with very appealing results." , Torrent ...
Breaking Biology News(10 mins):No danger of cancer through gene therapy virus 2Novel enzyme from tiny gribble could prove a boon for biofuels research 2The American Society for Microbiology honors Marc Torrent 2
... German . , Cystic kidney disease, renal ... excretory organs are characterized by overproduction or on ... renal cells. An international research team under the leadership ... now developed an animal model to better investigate these ...
... the origins of many serious diseases remain a mystery? ... California, San Diego School of Medicine has come up with ... the cell, which may provide an answer. Reviewing ... Professor of Cellular and Molecular Medicine and Investigator with the ...
... (Sept. 3, 2008) Scientists at the U.S. Department ... $800,000 EUREKA award from the National Institutes of Health ... measuring distances within a protein. MADMAX, ... Angle X-ray solution scattering, would not only dramatically reduce ...
Cached Biology News:Gaining a better understanding of kidney diseases 2Do 68 molecules hold the key to understanding disease? 2NIH awards Argonne $800,000 to develop tool to measure distances within proteins 2
... designed for two-dimensional electrophoresis (2D) and ... in this marker have been selected ... a 2D gel. The pI range ... Mol wt: 17,000-89,000 Physical Form: ...
... The M-840 HEXALIGHT robot is based on ... (PKM) over more than a decade. PI ... for mirror and antenna adjustments over wide ... provides six degrees of freedom with 3 ...
... offers a full length insert sequencing service ... cosmids and fosmids. Agencourt utilizes unique ... libraries. There are several features that ... data with rapid turnaround including our patented ...
... On-Demand Cytometry The Guava EasyCyte system ... based multiparameter cytometer with built-in 96-well microplate ... screen plates of cells and compounds quickly ... multiple tubes or having the carryover issues ...
Biology Products: